Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
901119-35-5
Molecular formula
C23H26FN6O9P
Molecular weight
580.5 g/mol
Drug class
Spleen tyrosine kinase (SYK) inhibitorimmunomodulatory small molecule
Mechanism of action
Fostamatinib is converted to the active metabolite R406, which inhibits SYK signalling downstream of Fc receptors in macrophages and other immune cells. This reduces antibody-mediated platelet phagocytosis in immune thrombocytopenia.
Indications / reported uses
Treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Fostamatinib PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Fostamatinib Permitted Daily Exposure (PDE) report (the Fostamatinib PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Fostamatinib Occupational Exposure Limit (OEL) report (the Fostamatinib OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.